Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6753702 | 0.85 | ALDH1A1 (0.43) | ALDH1A1TUBB1KMT2APOLBL3MBTL1 | |
| SCHEMBL9327164 | 0.84 | ERN1 (0.44) | ALDH1A1TUBB1KMT2APOLBL3MBTL1 | |
| SCHEMBL736351 | 0.83 | POLB (0.50) | ALDH1A1TUBB1KMT2APOLBERN1 | |
| SCHEMBL10603279 | 0.80 | BCHE (0.48) | ALDH1A1TUBB1KMT2AL3MBTL1ERN1 | |
| SCHEMBL7961321 | 0.80 | ALDH1A1 (0.36) | ALDH1A1TUBB1KMT2APOLBCYP1A2 | |
| SCHEMBL10604927 | 0.79 | SMN1; SMN2 (0.40) | ALDH1A1TUBB1KMT2APOLBL3MBTL1 | |
| SCHEMBL3213856 | 0.78 | SRC (0.56) | ALDH1A1POLBCYP1A2L3MBTL1ERN1 | |
| SCHEMBL4898660 | 0.76 | ALDH1A1 (0.50) | ALDH1A1KMT2APOLBCYP1A2L3MBTL1 | |
| SCHEMBL8731801 | 0.75 | POLB (0.44) | ALDH1A1TUBB1KMT2APOLBERN1 | |
| SCHEMBL30973586 | 0.75 | ERN1 (0.55) | ALDH1A1TUBB1CYP1A2L3MBTL1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | ALDH1A1 51/4885TUBB1 3032/4885KMT2A 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.